Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shovan Naskar
Institution:
Banaras Hindu University
Observed institutions:
Guru Nanak Institute of Pharmaceutical Science and Technology,
Indian Institute of Technology BHU,
Banaras Hindu University
ORCID:
0009-0004-9600-8003
Observed ORCID:
0009-0004-9600-8003
OpenAlex ID:
A5102649035
Nanoparticles engineering strategies for lymph-node targeted cancer immunotherapy
2025
·
Hitesh Harsukhbhai Chandpa
, Anuradha Gupta
, et al.
·
Nano Trends
·
6
Development and Optimization of Sustained-Release Matrix Tablets of Diclofenac Sodium Using Carboxymethylated Chitosan Through Systematic Application of Design of Experiments
2024
·
Debabrata Ghosh Dastidar
, Amit Biswas
, et al.
·
Drug Metabolism and Bioanalysis Letters
·
4
Super epitope dengue vaccine instigated serotype independent immune protection in-silico
2024
·
Shovan Naskar
, Hitesh Harsukhbhai Chandpa
, et al.
·
Vaccine
·
4
Dominant B cell-T cell epitopes instigated robust immune response in-silico against Scrub Typhus
2024
·
Shalini Agarwal
, Hitesh Harsukhbhai Chandpa
, et al.
·
Vaccine
·
2
Computer Integrated Dominant Epitopes Evoke Protective Immune Response Against Streptococcus pneumoniae
2025
·
Hitesh Harsukhbhai Chandpa
, Shovan Naskar
, et al.
·
Immunology
·
1
PDF
Engineering virus-like particles for lymph-node targeted cancer immunotherapy: strategies, challenges, and future prospects
2026
·
Hitesh Harsukhbhai Chandpa
, Ruchika
, et al.
·
Drug Discovery Today
Clinical Validations of Localized Cancer Nanomedicine
2025
·
Hitesh Harsukhbhai Chandpa
, Shovan Naskar
, et al.
·
Springer eBooks
Show more works
View as search
Works count:
7
Citation count:
17
H-index:
3
I10-index:
Year
Topic
Type
